Marianne Fonck
Marianne Fonck is an expert in Oncology at Institut Bergonié (France). Marianne Fonck has authored 71 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 214 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 71
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature. PMID 42688649 — oxaliplatin, signs and symptoms | Ther Adv Drug Saf | 2026 | 1 |
| Corrigendum to 'Impact on survival without chemotherapy of local treatments of lung metastasis of colorectal cancers: Analysis on REPULCO cohort' [Digestive and Liver Disease 56 (2024) 1930-7]. PMID 40877066 — liver diseases, lung, drug therapy, liver, neoplasm metastasis, therapeutics, colorectal neoplasms, chemotherapy | Dig Liver Dis | 2025 | 0 |
| Impact on survival without chemotherapy of local treatments of lung metastasis of colorectal cancers: Analysis on REPULCO cohort. PMID 38763795 — digestive system diseases, drug therapy, neoplasm metastasis, therapeutics, colorectal neoplasms, lung, disease-free survival, progression-free survival, chemotherapy | Dig Liver Dis | 2024 | 0 |
| Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should mutation research be recommended in everyday practice? PMID 38250014 — diagnosis, research design, adenocarcinoma, needles, therapeutics, mutation, biopsy, fine-needle, endoscopic ultrasound-guided fine needle aspiration | Therap Adv Gastroenterol | 2024 | 0 |
| First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. PMID 37563240 — molecular biology, drug therapy, therapeutics, colorectal neoplasms, microsatellite repeats, safety, t-lymphocytes, disease-free survival, genes, ras, epithelial-mesenchymal transition, progression-free survival, chemotherapy | Nat Med Top journal | 2023 | 46 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map